KemPharm (NASDAQ:KMPH) Shares Up 6.3%

KemPharm Inc (NASDAQ:KMPH) shares shot up 6.3% on Thursday . The stock traded as high as $0.53 and last traded at $0.51, 298,057 shares were traded during trading. An increase of 71% from the average session volume of 174,779 shares. The stock had previously closed at $0.48.

Several brokerages have recently weighed in on KMPH. Zacks Investment Research upgraded shares of KemPharm from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a research note on Friday, October 25th. Roth Capital downgraded shares of KemPharm from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $4.25 to $1.05 in a research note on Thursday, September 5th. ValuEngine upgraded shares of KemPharm from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of KemPharm in a research note on Thursday, September 5th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $1.89.

The firm has a market cap of $15.78 million, a price-to-earnings ratio of -0.20 and a beta of 1.39. The firm’s 50 day moving average price is $0.60 and its two-hundred day moving average price is $1.14.

KemPharm (NASDAQ:KMPH) last announced its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.09. Equities analysts forecast that KemPharm Inc will post -1.25 EPS for the current year.

In other news, CEO Travis C. Mickle purchased 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 24th. The stock was purchased at an average cost of $0.79 per share, with a total value of $39,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,713,117 shares of the company’s stock, valued at approximately $1,353,362.43. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have purchased 73,000 shares of company stock valued at $58,237 over the last three months. 14.90% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Wedbush Securities Inc. raised its holdings in KemPharm by 738.5% during the third quarter. Wedbush Securities Inc. now owns 97,430 shares of the specialty pharmaceutical company’s stock worth $67,000 after purchasing an additional 85,810 shares in the last quarter. Vanguard Group Inc. raised its holdings in KemPharm by 134.5% during the second quarter. Vanguard Group Inc. now owns 1,337,571 shares of the specialty pharmaceutical company’s stock worth $2,341,000 after purchasing an additional 767,100 shares in the last quarter. BlackRock Inc. raised its holdings in KemPharm by 21.7% during the second quarter. BlackRock Inc. now owns 106,490 shares of the specialty pharmaceutical company’s stock worth $186,000 after purchasing an additional 19,001 shares in the last quarter. Iowa State Bank raised its holdings in KemPharm by 90.6% during the second quarter. Iowa State Bank now owns 44,171 shares of the specialty pharmaceutical company’s stock worth $77,000 after purchasing an additional 21,000 shares in the last quarter. Finally, RDA Financial Network purchased a new position in KemPharm during the second quarter worth about $28,000. 25.44% of the stock is owned by hedge funds and other institutional investors.

KemPharm Company Profile (NASDAQ:KMPH)

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder.

Read More: Short Selling Stocks and Day Traders

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.